272 related articles for article (PubMed ID: 16047147)
21. [Establishment of a whole-body visualization model of breast cancer with high hepatic metastatic potential in nude mice through serial passage in vivo].
Yang M; Yang ZH; Hou ZD; Li XN
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jun; 28(6):944-7. PubMed ID: 18583234
[TBL] [Abstract][Full Text] [Related]
22. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
[TBL] [Abstract][Full Text] [Related]
23. In vivo uptake of carbon-14-colchicine for identification of tumor multidrug resistance.
Mehta BM; Rosa E; Biedler JL; Larson SM
J Nucl Med; 1994 Jul; 35(7):1179-84. PubMed ID: 8014680
[TBL] [Abstract][Full Text] [Related]
24. FemtoMolar measurements using accelerator mass spectrometry.
Salehpour M; Forsgard N; Possnert G
Rapid Commun Mass Spectrom; 2009 Mar; 23(5):557-63. PubMed ID: 19177507
[TBL] [Abstract][Full Text] [Related]
25. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
26. Detection of adriamycin-DNA adducts by accelerator mass spectrometry.
Coldwell K; Cutts SM; Ognibene TJ; Henderson PT; Phillips DR
Methods Mol Biol; 2010; 613():103-18. PubMed ID: 19997880
[TBL] [Abstract][Full Text] [Related]
27. Chemoprotection effect of multidrug resistance 1 (MDR1) gene transfer to hematopoietic progenitor cells and engrafted in mice with cancer allows intensified chemotherapy.
Guo C; Jin X
Cancer Invest; 2006 Nov; 24(7):659-68. PubMed ID: 17118775
[TBL] [Abstract][Full Text] [Related]
28. In vivo metabolism of epothilone B in tumor-bearing nude mice: identification of three new epothilone B metabolites by capillary high-pressure liquid chromatography/mass spectrometry/tandem mass spectrometry.
Blum W; Aichholz R; Ramstein P; Kühnöl J; Brüggen J; O'Reilly T; Flörsheimer A
Rapid Commun Mass Spectrom; 2001; 15(1):41-9. PubMed ID: 11135423
[TBL] [Abstract][Full Text] [Related]
29. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors.
Laginha KM; Verwoert S; Charrois GJ; Allen TM
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6944-9. PubMed ID: 16203786
[TBL] [Abstract][Full Text] [Related]
30. Dermatan carriers for neovascular transport targeting, deep tumor penetration and improved therapy.
Ranney D; Antich P; Dadey E; Mason R; Kulkarni P; Singh O; Chen H; Constantanescu A; Parkey R
J Control Release; 2005 Dec; 109(1-3):222-35. PubMed ID: 16290245
[TBL] [Abstract][Full Text] [Related]
31. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
32. Extensive intracellular accumulation of ID-6105, a novel anthracycline, in SK-OV-3 ovarian cancer cells.
Shin DH; Choi KS; Park SA; Cho BS; Lee HS; Ryu JS; Kim TY; Lee CK; Song S; Chung YB
Arch Pharm Res; 2008 Oct; 31(10):1355-61. PubMed ID: 18958428
[TBL] [Abstract][Full Text] [Related]
33. Preclinical evaluation of the breast cancer cell-binding peptide, p160.
Askoxylakis V; Zitzmann S; Mier W; Graham K; Krämer S; von Wegner F; Fink RH; Schwab M; Eisenhut M; Haberkorn U
Clin Cancer Res; 2005 Sep; 11(18):6705-12. PubMed ID: 16166451
[TBL] [Abstract][Full Text] [Related]
34. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
Saucier JM; Yu J; Gaikwad A; Coleman RL; Wolf JK; Smith JA
J Oncol Pharm Pract; 2007 Mar; 13(1):39-45. PubMed ID: 17621566
[TBL] [Abstract][Full Text] [Related]
35. HPLC quantification of doxorubicin in plasma and tissues of rats treated with doxorubicin loaded poly(alkylcyanoacrylate) nanoparticles.
Alhareth K; Vauthier C; Gueutin C; Ponchel G; Moussa F
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Mar; 887-888():128-32. PubMed ID: 22341684
[TBL] [Abstract][Full Text] [Related]
36. The performance of doxorubicin encapsulated in chitosan-dextran sulphate microparticles in an osteosarcoma model.
Tan ML; Friedhuber AM; Dunstan DE; Choong PF; Dass CR
Biomaterials; 2010 Jan; 31(3):541-51. PubMed ID: 19836833
[TBL] [Abstract][Full Text] [Related]
37. A safer method for studying hormone metabolism in an Asian elephant (Elephas maximus): accelerator mass spectrometry.
Yon L; Faulkner B; Kanchanapangka S; Chaiyabutr N; Meepan S; Lasley B
Zoo Biol; 2010; 29(6):760-6. PubMed ID: 20127658
[TBL] [Abstract][Full Text] [Related]
38. Accelerator mass spectrometry analysis of background (14)C-concentrations in human blood: aiming at reference data for further microdosing studies.
Minamimoto R; Hamabe Y; Miyaoka T; Hara T; Yoshida K; Oka T; Inoue T
Ann Nucl Med; 2008 Dec; 22(10):883-9. PubMed ID: 19142707
[TBL] [Abstract][Full Text] [Related]
39. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
